Spain’s competition watchdog, CNMC, has started investigation proceedings against Grifols SA, which may face fines and sanctions stemming from their failure to notify authorities of their merger and acquisitions plans.
The CNMC authorized the first phase of Grifols takeover of Novartis International’s blood transfusion diagnostics division, which was bought by the Spanish multinational on March 25. However, the CNMC would have received the formal notification documents only ten days prior, on March 10th.
The relevant merger operations, meanwhile, would have taken place over one year prior, in early January 2014. Spain’s competition laws force businesses to notify the CNMC of any merger before it is carried out. Due to the timeline presented to the regulator, the CNMC has determined it necessary to investigate whether or not this rule was violated by the pharmaceuticals multinational.
Full content: CNMC
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Redfin Settles $9.2M Commission Inflation Lawsuits
May 7, 2024 by
CPI
DOJ Supports Colorado’s Efforts to Block Kroger-Albertsons Merger
May 7, 2024 by
CPI
Japan Considers Regulation of AI Developers
May 7, 2024 by
CPI
European Commission Extends Decision Deadline for Ita-Lufthansa Merger
May 7, 2024 by
CPI
UK, US and Australia Sanction Senior Leader of LockBit Cybercrime Gang
May 7, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI